Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Neuroinflammation. 2019 Jun 8;16(1):123. doi: 10.1186/s12974-019-1508-2.

Soluble epoxide hydrolase modulates immune responses in activated astrocytes involving regulation of STAT3 activity.

Author information

1
Institute of Physiology, Brain Research Center, National Yang-Ming University, Taipei, Taiwan, Republic of China.
2
Center for Neuropsychiatric Research, National Health Research Institutes, No.35 Keyan Road, Zhunan Town, Miaoli County, 350, Taiwan, Republic of China.
3
Institute of Neuroscience, Brain Research Center, National Yang-Ming University, Taipei, Taiwan, Republic of China.
4
Center for Neuropsychiatric Research, National Health Research Institutes, No.35 Keyan Road, Zhunan Town, Miaoli County, 350, Taiwan, Republic of China. fshie@nhri.org.tw.

Abstract

BACKGROUND:

Astrocyte activation is a common pathological feature in many brain diseases with neuroinflammation, and revealing the underlying mechanisms might shed light on the regulatory processes of the diseases. Recently, soluble epoxide hydrolase (sEH) has been proposed to affect neuroinflammation in brain injuries. However, the roles of astrocytic sEH in brains with neurodegeneration remain unclear.

METHODS:

The expression of astrocytic sEH in the brains of APPswe/PSEN1dE9 (APP/PS1) mice developing Alzheimer's disease (AD)-like pathology was evaluated by confocal imaging. LPS-activated primary astrocytes with mRNA silencing or overexpression of sEH were used to investigate its regulatory roles in astrocyte activation and the induction of pro-inflammatory markers. Primary astrocytes isolated from a sEH knockout (sEH-/-) background were also applied.

RESULTS:

The immunoreactivity of sEH was increased in activated astrocytes in parallel with the progression of AD in APP/PS1 mice. Our data from primary astrocyte cultures further demonstrate that the overexpression of sEH ameliorated, while the silencing of sEH mRNA enhanced, the lipopolysaccharides (LPS)-induced expression of pro-inflammatory markers, such as inducible nitric oxide, cyclooxygenase 2 (COX-2), and pro-inflammatory cytokines. These findings suggest that sEH negatively regulates astrocyte immune responses. Enhanced immune responses found in LPS-activated sEH-/- astrocytes also support the notion that the expression of sEH could suppress the immune responses during astrocyte activation. Similarly, sEH-/- mice that received intraperitoneal injection of LPS showed exacerbated astrocyte activation in the brain, as observed by the elevated expression of glial fibrillary acidic protein (GFAP) and pro-inflammatory markers. Moreover, our data show that the phosphorylation of the signal transducer and activator of transcription 3 (STAT3) was upregulated in activated astrocytes from sEH mouse brains, and the pharmacological blockade of STAT3 activity alleviated the pro-inflammatory effects of sEH deletion in LPS-activated primary astrocytes.

CONCLUSIONS:

Our results provide evidence, for the first time, showing that sEH negatively regulates astrocytic immune responses and GFAP expression, while the underlying mechanism at least partly involves the downregulation of STAT3 phosphorylation. The discovery of a novel function for sEH in the negative control of astrocytic immune responses involving STAT3 activation confers further insights into the regulatory machinery of astrocyte activation during the development of neurodegeneration.

KEYWORDS:

Astrocyte activation; GFAP; Immune responses; STAT3; Soluble epoxide hydrolase

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center